Cargando…
Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study
BACKGROUND: Endoscopic placement of hilar stents is an accepted palliative therapy for patients with advanced, unresectable cholangiocarcinoma. However, whether unilateral versus bilateral stent placement provides optimal relief continues to be a subject of debate. The aim of this study was to compa...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049245/ https://www.ncbi.nlm.nih.gov/pubmed/32127742 http://dx.doi.org/10.20524/aog.2020.0451 |
_version_ | 1783502401988198400 |
---|---|
author | Staub, Judith Siddiqui, Ali Murphy, Megan Lam, Robert Parikh, Meet Pleskow, Douglas Papachristou, Georgios Sharaiha, Reem Iqbal, Usama Loren, David Kowalski, Thomas Noor, Arish Mumtaz, Tayebah Yasuda, Ichiro Thomas, Samuel Hsaeeb, Abdul Herrick, Jennifer Greene, Tom Adler, Douglas G. |
author_facet | Staub, Judith Siddiqui, Ali Murphy, Megan Lam, Robert Parikh, Meet Pleskow, Douglas Papachristou, Georgios Sharaiha, Reem Iqbal, Usama Loren, David Kowalski, Thomas Noor, Arish Mumtaz, Tayebah Yasuda, Ichiro Thomas, Samuel Hsaeeb, Abdul Herrick, Jennifer Greene, Tom Adler, Douglas G. |
author_sort | Staub, Judith |
collection | PubMed |
description | BACKGROUND: Endoscopic placement of hilar stents is an accepted palliative therapy for patients with advanced, unresectable cholangiocarcinoma. However, whether unilateral versus bilateral stent placement provides optimal relief continues to be a subject of debate. The aim of this study was to compare the technical and clinical outcomes in patients with inoperable cholangiocarcinoma who received unilateral or bilateral self-expanding metal stents (SEMS). METHODS: We conducted a multicenter, international retrospective study of 187 patients with cholangiocarcinoma who received unilateral or bilateral SEMS. Outcomes included, but were not limited to, technical success, clinical success, adverse events, stent occlusion, and survival time. Results were further stratified based on the Bismuth classification. RESULTS: Fifty patients received unilateral stents and 137 patients received bilateral stents. All patients achieved technical success. The clinical success rates were 86% for unilateral stents and 82.5% for bilateral stents (P>0.99). Clinical success was not statistically different for either group when stratified by the Bismuth classification (P=0.62 and P=0.72 respectively). There were significantly more adverse events in the bilateral stents group (11.7% vs. 0%, P=0.007). There was no greater risk of stent occlusion when bilateral stents were used (unadjusted P=0.71, adjusted P=0.81). There was a greater risk of death for patients who received bilateral SEMS (hazard ratio 1.78, 95% confidence interval 1.09-2.89; P=0.02). CONCLUSIONS: Unilateral and bilateral drainage had similar technical and clinical success rates. However, bilateral stents had a higher risk of death and more adverse events. Therefore, unilateral SEMS placement is sufficient for relief of biliary obstruction secondary to cholangiocarcinoma. |
format | Online Article Text |
id | pubmed-7049245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hellenic Society of Gastroenterology |
record_format | MEDLINE/PubMed |
spelling | pubmed-70492452020-03-04 Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study Staub, Judith Siddiqui, Ali Murphy, Megan Lam, Robert Parikh, Meet Pleskow, Douglas Papachristou, Georgios Sharaiha, Reem Iqbal, Usama Loren, David Kowalski, Thomas Noor, Arish Mumtaz, Tayebah Yasuda, Ichiro Thomas, Samuel Hsaeeb, Abdul Herrick, Jennifer Greene, Tom Adler, Douglas G. Ann Gastroenterol Original Article BACKGROUND: Endoscopic placement of hilar stents is an accepted palliative therapy for patients with advanced, unresectable cholangiocarcinoma. However, whether unilateral versus bilateral stent placement provides optimal relief continues to be a subject of debate. The aim of this study was to compare the technical and clinical outcomes in patients with inoperable cholangiocarcinoma who received unilateral or bilateral self-expanding metal stents (SEMS). METHODS: We conducted a multicenter, international retrospective study of 187 patients with cholangiocarcinoma who received unilateral or bilateral SEMS. Outcomes included, but were not limited to, technical success, clinical success, adverse events, stent occlusion, and survival time. Results were further stratified based on the Bismuth classification. RESULTS: Fifty patients received unilateral stents and 137 patients received bilateral stents. All patients achieved technical success. The clinical success rates were 86% for unilateral stents and 82.5% for bilateral stents (P>0.99). Clinical success was not statistically different for either group when stratified by the Bismuth classification (P=0.62 and P=0.72 respectively). There were significantly more adverse events in the bilateral stents group (11.7% vs. 0%, P=0.007). There was no greater risk of stent occlusion when bilateral stents were used (unadjusted P=0.71, adjusted P=0.81). There was a greater risk of death for patients who received bilateral SEMS (hazard ratio 1.78, 95% confidence interval 1.09-2.89; P=0.02). CONCLUSIONS: Unilateral and bilateral drainage had similar technical and clinical success rates. However, bilateral stents had a higher risk of death and more adverse events. Therefore, unilateral SEMS placement is sufficient for relief of biliary obstruction secondary to cholangiocarcinoma. Hellenic Society of Gastroenterology 2020 2020-02-12 /pmc/articles/PMC7049245/ /pubmed/32127742 http://dx.doi.org/10.20524/aog.2020.0451 Text en Copyright: © Hellenic Society of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Staub, Judith Siddiqui, Ali Murphy, Megan Lam, Robert Parikh, Meet Pleskow, Douglas Papachristou, Georgios Sharaiha, Reem Iqbal, Usama Loren, David Kowalski, Thomas Noor, Arish Mumtaz, Tayebah Yasuda, Ichiro Thomas, Samuel Hsaeeb, Abdul Herrick, Jennifer Greene, Tom Adler, Douglas G. Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study |
title | Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study |
title_full | Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study |
title_fullStr | Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study |
title_full_unstemmed | Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study |
title_short | Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study |
title_sort | unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049245/ https://www.ncbi.nlm.nih.gov/pubmed/32127742 http://dx.doi.org/10.20524/aog.2020.0451 |
work_keys_str_mv | AT staubjudith unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT siddiquiali unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT murphymegan unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT lamrobert unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT parikhmeet unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT pleskowdouglas unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT papachristougeorgios unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT sharaihareem unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT iqbalusama unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT lorendavid unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT kowalskithomas unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT noorarish unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT mumtaztayebah unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT yasudaichiro unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT thomassamuel unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT hsaeebabdul unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT herrickjennifer unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT greenetom unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy AT adlerdouglasg unilateralversusbilateralhilarstentsforthetreatmentofcholangiocarcinomaamulticenterinternationalstudy |